Clinical trials: Recurrent Adenocarcinoma
Solid Tumor, Adult, Squamous Cell Carcinoma of Head and Neck
A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer
This is a phase 1/2, multi-center study with an open-label, dose escalation phase followed by a single-arm expansion phase to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 alone and in…
- Conditions
- Solid Tumor, Adult, Squamous Cell Carcinoma of Head and Neck, Colorectal Adenocarcinoma, Metastatic Solid Tumor
- Trial name
- NCT04474470
- Testing
- NT219, NT219 and ERBITUX® - Dose Escalation, NT219 and ERBITUX® - Expansion
- Where
- 10 sites in United States, Israel
- Volunteers
- 52 people
- Sponsor
- TyrNovo Ltd.
Primary Liver Cancer
Effect of SAMe Treatment on Recurrence After Radical Treatment of Primary Hepatic Carcinoma
The aim of this study is to explore the effect of SAMe on recurrence after radical treatment of Primary liver cancer.
- Trial name
- NCT03178929
- Testing
- S-Adenosyl Methionine
- Volunteers
- 207 people
- Sponsor
- Beijing Insight Science & Technology Co. Ltd.
Kidney Cancer
High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill renal cell carcinoma (kidney cancer) cells. PURPOSE: This phase II trial is studying how well high-dose intravenous interleukin-2 works in treating…
- Trial name
- NCT00080977
- Testing
- aldesleukin
- Where
- United States
- Sponsor
- Blumenthal Cancer Center at Carolinas Medical Center
Colorectal Cancer, Metastatic Cancer
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- ERBIFORT (NCT00557102)
- Testing
- cetuximab, filgrastim, fluorouracil
- Where
- France
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute, France
Liver Cancer, Metastatic Cancer
Quality of Life in Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres for Primary or Metastatic Liver Cancer
RATIONALE: Learning about quality of life in patients with cancer undergoing embolization may help doctors learn about the side effects of treatment and plan the best treatment.
- Trial name
- NCT00739167
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Northwestern University
Hepatocellular Carcinoma
The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
To compare The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy.
- Trial name
- NCT04053972
- Testing
- Lenvatinib
- Where
- China
- Volunteers
- 377 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Cryosurgery kills cancer cells by freezing them.
- Trial name
- NCT00008294
- Testing
- FOLFOX regimen, dexamethasone, floxuridine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Relapsed or Advanced Gastric Adenocarcinoma, Gastro-esophageal Junction Cancer
Investigator-initiated Pilot Study to Investigate the Efficacy and Safety of Immuncell-LC in Combination With Nivolumab (Opdivo) in Subjects With Advanced or Recurrent Gastric Cancer
This study was planned to evaluate the efficacy and safety of combination therapy of Immuncell-LC and nivolumab in patients with relapsed or advanced gastric adenocarcinoma or gastro-esophageal junction cancer.
- Trial name
- NCT05053295
- Testing
- autologous activated T lymphocyte
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Gangnam Severance Hospital
Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors.
- Conditions
- Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma
- Trial name
- NCT05039801
- Testing
- Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma
Evaluation of Liver Stiffness by Ultrasound Elastography for Predicting Early HCC Recurrence After Treatment
We aim to evaluate liver stiffness as a marker of severity and duration of the underlying liver disease to predict for early HCC recurrence after treatment.
- Trial name
- NCT04552236
- Testing
- Ultrasound ELastography
- Volunteers
- 100 people
- Sponsor
- Assiut University
Recurrent Neuroendocrine Carcinoma of the Skin, Stage I Neuroendocrine Carcinoma of the Skin
Oblimersen in Treating Patients With Merkel Cell Carcinoma
This phase II trial is studying how well oblimersen works in treating patients with Merkel cell cancer. Biological therapies, such as oblimersen, may interfere with the growth of tumor cells and slow the growth of Merkel cell…
- Conditions
- Recurrent Neuroendocrine Carcinoma of the Skin, Stage I Neuroendocrine Carcinoma of the Skin, Stage II Neuroendocrine Carcinoma of the Skin, Stage III Neuroendocrine Carcinoma of the Skin
- Trial name
- NCT00079131
- Testing
- oblimersen sodium, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
This randomized phase III trial studies carboplatin and paclitaxel to compare how well they work with or without bevacizumab and/or cetuximab in treating patients with stage IV or non-small cell lung cancer that has returned…
- Conditions
- Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Squamous Cell Lung Carcinoma, Stage IV Large Cell Lung Carcinoma
- Trial name
- NCT00946712
- Testing
- Bevacizumab, Carboplatin, Cetuximab
- Where
- 798 sites in United States, Mexico
- Volunteers
- 1,333 people
- Sponsor
- SWOG Cancer Research Network
Recurrent Adenocarcinoma of the Pancreas, Metastatic Adenocarcinoma of the Pancreas
Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas
Phase II Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas.
- Trial name
- NCT02739633
- Testing
- Genexol-PM, Gemcitabine
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Intrahepatic Cholangiocarcinoma
PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery
SHR-1210 is a humanized anti-PD-1 Immunoglobulin G4 (IgG4) monoclonal antibody. This is an open- label,single center,non-randomized ,single arm exploratory study .
- Trial name
- NCT04295317
- Testing
- PD-1 blocking antibody SHR-1210, Capecitabine
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Shanghai Zhongshan Hospital
HCC
Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
Primary liver cancer is one of the most common malignant tumors in the world, and about 80%~90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC).
- Trial name
- NCT06420440
- Testing
- Hepatic arterial infusion chemotherapy, Lenvatinib, Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Chen Xiaoping
Cervical Cancer
Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, topotecan, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00276796
- Testing
- cisplatin, paclitaxel, topotecan hydrochloride
- Volunteers
- 66 people
- Sponsor
- Gynecologic Oncology Group
Recurrent Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma
Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
This phase I/II trial studies the side effects and best way to give laboratory treated autologous T cells together with aldesleukin and to see how well it works in treating patients with merkel cell carcinoma that has spread from…
- Trial name
- NCT01758458
- Testing
- Aldesleukin, Laboratory Biomarker Analysis, MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Fred Hutchinson Cancer Center
Prostate Cancer
R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have progressive…
- Trial name
- NCT00005848
- Testing
- chemotherapy, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Fox Chase Cancer Center
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer
This phase II trial is studying how well giving sorafenib with interferon alfa works in treating patients with metastatic or unresectable kidney cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00101114
- Testing
- sorafenib tosylate, recombinant interferon alfa-2b, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
This phase II trial studies how well giving selumetinib and erlotinib hydrochloride together works in treating patients with locally advanced or metastatic pancreatic cancer that is refractory to chemotherapy.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT01222689
- Testing
- erlotinib hydrochloride, selumetinib, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)